Table 1 Demographics, prodromal symptoms and diagnostics in the identified NORSE subgroups
From: Early clinical features of new-onset refractory status epilepticus (NORSE) in adults
All patients (n = 19) | FIRES (n = 6) | Viral encephalitis (n = 5) | Afebrile NORSE group (n = 8) | FIRES vs non-FIRES | |
|---|---|---|---|---|---|
Demographics | |||||
Female | 11 (58%) | 3 (50%) | 2 (40%) | 6 (75%) | NS |
Age at onset | 55 (27-65) | 21 (19-24) | 64 (55-64) | 67 (59-71) | p = 0.001 |
Comorbidities | 10 (53%) | 0 | 3 (60%) | 6 (75%) | p = 0.011 |
Prodromal symptoms | |||||
fever | 10 (53%) | 6 (100%) | 4 (80%) | 0 | NS |
headache | 5 (26%) | 2 (33%) | 3 (60%) | 0 | NS |
respiratory symptoms | 4 (21%) | 4 (67%) | 0 | 0 | p = 0.004 |
gastrointestinal symptoms | 4 (21%) | 2 (33%) | 2 (40%) | 0 | NS |
cognitive symptoms | 5 (26%) | 0 | 1 (20%) | 4 (50%) | NS |
psychiatric symptoms | 1 (5%) | 0 | 0 | 1 (12.5%) | NS |
Diagnostics | |||||
First brain MRI | |||||
abnormal | 7 (37%) | 0 | 4 (80%) | 3 (37.5%) | p = 0.044 |
not performed | 2 (11%) | 1 (16.5%)a | 1 (20%)a | 0 | NS |
SF | |||||
pleocytosisb | 8 (42%) | 2 (33%) | 4 (80%) | 3 (37.5%) | NS |
elevated proteinsc | 9 (47%) | 1 (17%) | 4 (80%) | 4 (50%) | NS |
diagnostic findings | HSV-1 PCR+ (4) TBE Ab+ (1) | ||||
Ictal EEG | |||||
focal | 11 (58%) | 3(50%) | 3 (60%) | 5 (62.5%) | NS |
multifocal | 3 (16%) | 2 (33%) | 0 | 1 (12.5%) | NS |
generalized | 1 (5%) | 0 | 0 | 1 (12.5%) | NS |
not available | 4 (21%) | 1 (17%) | 2 (40%) | 1 (12.5%) | NS |